Literatuur– en Referentielijst
Annemans L, Cleemput I, Hulstaert F. & Simoens S. Valorising and creating access to innovative medicines in the European union. Front Pharmacol. 2011;2:57.
Chester S. Galloway, (2003) "Misplaced marketing Misplaced fears of off-label prescription drug marketing", Journal of Consumer Marketing, Vol. 20 Iss: 6, pp.513 – 515
Drummond M, Jönsson B, Rutten F. & Stargardt T. Reimbursment of pharmaceuticals: refernce pricing versus health technology assessment. Eur J Health Econ (2011) 12:263-271
Ess SM, Schneeweiss S & Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics. 2003;21(2):89-103.
Green CJ, Maclure M, Fortin PM, Ramsay CR, Aaserud M, Bardal S. Pharmaceutical policies : effects of restrictions on reimbursment( Review ) Cochrane Database of Systematic Reviews 2010, Issue 8 : 1-92
Gress S., Niebuhr D., May U. & Wasem J. Reform of prescription drug reimbursement and pricing in the German social he25495200alth insurance market: a comparison of three scenarios. Pharmacoeconomics. 2007;25(6):443-54.
KCE rapport 147A. Terugbetalingsystemen voor geneesmiddelen: internationale vergelijking en beleidsaanbevelingen.
Koopmanschap MA. & Rutten FF. The drug budget silo mentality: the Dutch case. Value Health. 2003 Jul-Aug;6 Suppl 1:S46-51.
Larrat E. P., RPh, PhD; Marcoux R.M., RPh, MBA; and Vogenberg F.R., RPh, PhD; Impact of Federal and State Legal Trends On Health Care Services; Health Care and Law, April 2012 • Vol. 37 No. 4
le Polain M, Franken M, Koopmanschap M, Cleemput I. Terugbetalingssystemen voor geneesmiddelen: internationale vergelijking en beleidsaanbevelingen. Health Services Research (HSR). Brussel: Federaal Kenniscentrum voor de Gezondheidszorg (KCE). 2010. KCE Reports 147A.
ÖBIG (2006). Surveying, Assessing and Analyzing the Pharmaceutical Sector in the 25 EU Member States. Available at: http://ec.europa.eu/comm/competi- tion/mergers/studies_reports/oebig.pdf
Papatheofanis FJ. Health technology assessment. Q J Nucl Med. 2000 Jun;44(2):105-11.
Puig-Junoy Jaume et al. Impact of pharmaceutical prior authorisation policies.(2007) Pharmaeconomics vol 25(8) : 637-648
Rosery H., Reimbursement of Drugs in Germany: A Road Map for the Approval Process, 2006, Analytica International GmbH, Loerrach, Germany
RIZIV - DGEC, Activiteitenverslag 2011
Safran D., Patricia Neuman, Cathy Schoen, Jana E. Montgomery, Wenjun Li, Ira B. Wilson, Michelle S. Kitchman, Andrea E. Bowen, and William H. Rogers, Prescription Drug Coverage And Seniors: How Well Are States Closing The Gap?, July 2002, Health Affairs – Web Exclusive
Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011 Jun 17;6:42. PubMed PMID: 21682893; PubMed Central PMCID: PMC3132155.
Frank Peys; Pricing and Reimbursement Systems in Europe - The pharma sector and its financing in Belgium; The European Journal of Health Economics, Volume 2, Number 1 (2001), 33-38, DOI: 10.1007/PL00012217